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Abstract
Prion diseases are progressive neurodegenerative diseases that are associated with the
conformational conversion of normal cellular prion protein (PrPC) into abnormal patho-
genic prion protein (PrPSc). PrPC is a metal-binding protein that is located in the synapse
and possesses the ability to bind to various metals, including Cu, Zn, Mn and Fe.
Moreover, increasing evidence suggests that PrPC plays essential roles in the mainte-
nance of metal homeostasis in the synapse. Trace elements have a crucial influence on
the conformational change of PrPC. Given that other disease-related proteins such as
β-amyloid protein and its precursor protein (APP) in Alzheimer's disease also exist in
the synapse and possess a metal-binding ability, an interaction between PrP and metals
and between PrP and APP, may occur in the synapse; the resulting metal homeostasis
may lead to the pathogenesis of prion diseases. Here, we review our studies and other
new findings that inform the current understanding of the link between trace elements
and physiological functions of PrPC and the neurotoxicity of PrPSc.
Keywords: Alzheimer's disease, synapse, calcium homeostasis, zinc, copper, iron,
manganese
1. Introduction
Prion diseases are fatal neurodegenerative diseases, such as scrapie in sheep, bovine spongiform
encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-
Scheinker syndrome (GSS) and Kuru in humans [1]. The common pathological hallmarks of
prion diseases are the spongiform degeneration of glial cells and neurons. The accumulation of
amyloidogenic prion protein (PrP) as the abnormal scrapie type isoform (PrPSc) is also
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
observed in the brain of patients. Prion diseases are also called transmissible spongiform
encephalopathies because their infection characteristics are caused by the activities of PrPSc in
the pathogenetic tissues [2].
Although the molecular pathogenesis and transmission pathway of prion diseases are still
controversial, it is widely accepted that the conformational conversion of normal cellular
prion protein (PrPC) into an abnormal PrPSc is the transmissible characteristic of prion
diseases. Normal PrPC is a 30–35 kDa cell surface glycoprotein anchored at the plasma
membrane with a glycosylphosphatidylinositol (GPI) domain. PrPC is ubiquitously
expressed in the body and notably expressed in the brain. Both PrPC and PrPSc have the
same characteristic chemical modification of the same primary sequence. However, PrPC
differs from PrPSc in terms of resistance to protease digestion, a high content of β-sheet
secondary structure and the propensity to form insoluble amyloid fibrils. When the
misfolded PrPSc enters into the body via the ingestion of contaminated food, etc., the
protease-resistant PrPSc can aggregate, resulting in fibril formation that in turn promotes
other PrPC molecules in the brain to misfold and aggregate. These lines of evidence
suggest that the conformational change of PrP is crucial for the pathogenesis of prion
diseases. Thus, prion diseases are included in the category of protein-misfolding diseases
(conformational diseases), along with Alzheimer's disease (AD), triplet repeat diseases and
dementia with Lewy bodies (DLB) [3]. All of these diseases share common properties,
such as the deposition of disease-related proteins (amyloids) and in the exhibition of
neurotoxicity. The disease-related proteins, which are termed amyloidogenic proteins,
include β-amyloid protein (AβP) in AD, prion protein in prion diseases, polyglutamine in
triplet repeat disease and α-synuclein in DLB. Although their primary sequences are
identical, all of these proteins form insoluble fibril-like structures (amyloid fibrils) with β-
pleated sheet structures. Furthermore, all of these amyloidogenic proteins possess the ability
to bind trace metals [4].
In the brain, considerable amounts of trace elements such as iron (Fe), zinc (Zn), copper (Cu)
and manganese (Mn) exist, as well as other ubiquitous elements such as sodium (Na), potas-
sium (K), calcium (Ca) and magnesium (Mg). The concentration and the distribution of each
metal differ across brain regions [5, 6]. These trace elements are essential for the normal brain
functions. However, an excess of these metals are neurotoxic. Thus, their concentration and
chemical form are strictly regulated.
Increasing evidence suggests that trace elements are involved in the neurodegenerative
pathways for prion diseases [7]. There are three possible roles for trace elements in these
neurodegenerative pathways [8]: (1) supporting the “loss of the normal, protective func-
tions of PrPC”; (2) supporting a “gain of toxic functions of PrPSc”; and (3) “a combination
of both.” Although the physiological roles of PrPC are not yet fully understood despite its
wide distribution, several studies suggest that PrPC regulates metal homeostasis and has
antioxidant and cytoprotective effects against the neurotoxicity induced by Cu2+ or free
radicals. Therefore, the depletion of PrPC and the resulting metal dyshomeostasis may
trigger the neurodegenerative processes. Moreover, PrPSc and its fragment peptides cause
synaptic impairment and apoptosis in neurons or astrocytes in vitro or in vivo [9, 10]. Trace
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elements cause conformational changes in PrP and enhance its neurotoxicity. Furthermore,
prion plaques in the patient brain reportedly contain low Cu and high Mn [11]. The
expression level of PrP is correlated with the distribution of metals [12]. Here, we review
our studies and other new findings for a current understanding of the link between trace
elements and the pathogenesis of prion diseases. We also discuss the role of PrP as the
regulator of metal homeostasis and the protector against neurotoxicity of β-amyloid pro-
tein (AβP) at the synapse.
2. Metal homeostasis and normal prion protein
2.1. Cu and normal prion protein
Cu is the third most abundant metal in the brain. Cu is essential for brain function and is a
cofactor for numerous enzymes, including cytochrome C, superoxide dismutase, lysyl oxi-
dase and tyrosinase. Cu is involved in Fe homeostasis as a component of ceruloplasmin.
Moreover, Cu has neuroprotective activity as a component of Cu/Zn superoxide dismutase
(Cu/ZnSOD), an endogenous antioxidant. Thus, Cu deficiency has adverse effects on
myelination. However, Cu is a redox-active metal and exists as both oxidized Cu2+ and
reduced Cu+. Excess free Cu is toxic because it produces ROS and binds with the thiol
groups of functional proteins. Cu binds to transporter proteins such as CTR1, ATP7A and
ATP7B and is transported into the brain. Cu deficiency or excess due to an impairment of
these transporters leads to severe neurodegenerative diseases such as Wilson's disease or
Menkes disease.
Recent studies suggest that Cu has modulatory effects on neuronal information processes
[13–15]. Intracellular Cu accumulates in synaptic vesicles and is then released into the
synaptic clefts during neuronal excitation at the concentration about 15–100 μM. These
characteristics are quite similar to Zn. The released Cu reportedly influences various
receptors, including N-methyl-D-aspartate (NMDA)-type glutamate receptor, AMPA-type
glutamate receptor and GABA receptor to modulate the neuronal activity [16].
The link between Cu and prion diseases were first reported by Brown et al. in 1997 [17]. They
demonstrated that the levels of Cu in the brains of PrP-knockout mice are significantly
decreased compared to those levels in normal mice. The activity of Cu-dependent enzymes
was also reduced in PrP-null mice. As shown in Figure 1, PrPC contains 208 amino acid
residues and possesses a highly conserved octarepeat domain composed of multiple tandem
copies of the eight-residue sequence PHGGGWGQ in its N-terminal (Figure 1). Jackson et al.
reported that PrPC binds to four Cu atoms in its octarepeat domain and binds to two Cu
atoms in addition to two histidine (His) residues, His96 and His111 [18]. They also demon-
strated that other metals including Zn2+, Mn2+ and Ni2+ bind to these binding sites with
lower affinities compared to Cu2+. Extended X-ray absorption fine structure (EXAFS) spec-
troscopy demonstrated that Cu binds His residues in the octarepeat domain [19]. Moreover,
Valensin et al. reported that His111 in the neurotoxic fragment PrP106-126 has the ability to
bind Cu+ and Ag+ [20].
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PrPC reportedly transports Cu from the extracellular space to the intracellular space via
endocytosis and thus regulates the intracellular concentrations of Cu [21]. Furthermore,
PrP possesses or modulates Cu/ZnSOD activity in the brain and plays roles in the cellular
resistance to oxidative stress [22]. Indeed, PrP-deficient neurons exhibit a lower glutathi-
one activity and susceptibility to hydrogen peroxide [23]. Recent studies suggest that PrPC
regulates the excitability of NMDA-type glutamate receptor in a Cu-dependent manner [24].
Moreover, Cu2+ influences the gene expression and cellular trafficking of PrP [25]. PrPSc-
infected cells exhibit decreased Cu2+ binding. The Cu-deficient condition due to a mutation
of ATP7A delays the onset of prion diseases. These results indicate that the regulation of Cu
homeostasis is involved in the physiological roles of PrP and its mechanism of infection and
neurodegeneration.
These characteristics of PrPC are similar to those of the AD-related protein AβP (Figure 1).
AβP is a small peptide of 39–43 amino acid residues, which results from a cleavage of a
large precursor protein (APP; amyloid precursor protein). The conformational change of
AβP and its neurotoxicity play central roles in the pathogenesis of AD [26]. APP has
distinct binding domains for Cu, Zn and Fe. APP binds to Cu with its N-terminal and
converts Cu2+ into Cu+ [27]. Cu influences the expression and the dimerization of APP
and the trafficking of APP from the ER to the neurites. Moreover, Cu promotes the
production of AβP.
Figure 1. The structure and the metal-binding properties of prion protein and APP.
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2.2. Zn and normal prion protein
Other metals are also associated with prion diseases. Among them, Zn2+ has the next
highest binding affinity to PrPC compared to Cu2+. Zn is the second most abundant element
in the brain. Zn is essential for most organisms and plays important roles in various
physiological functions such as mitotic cell division, immune system functioning and syn-
thesis of proteins and DNA [28]. Moreover, Zn acts as a cofactor to more than 300 enzymes
or metalloproteins. Recent studies have revealed that Zn signaling plays crucial roles as a
second messenger in various human biological systems. Thus, Zn deficiency in children
results in dwarfism, delayed mental and physical development, immune dysfunction and
learning disabilities. Zn deficiency also produces learning disorders, taste disorders and
odor disorders in adults.
The human body contains approximately 2 g of Zn. In the brain, Zn is concentrated in the
regions such as cerebral cortex, amygdala, hippocampus, thalamus and olfactory cortex. Zn in
the brain firmly binds to metalloproteins or enzymes. However, a substantial fraction (approx-
imately 10% or more) of Zn either forms free Zn ions (Zn2+) or is loosely bound. This Zn
fraction is histochemically detectable via staining with chelating reagents [29]. In the presyn-
aptic vesicles of excitatory glutamatergic neurons, the chelatable Zn is stored and is secreted
into synaptic clefts together with glutamate during neuronal firings. The concentration of this
secreted Zn is estimated to be 1–100 μM [30, 31]. Secreted Zn2+ modulates overall brain
excitability by binding with N-methyl-D-aspartate (NMDA)-type glutamate receptors, GABA
receptors and glycine receptors. The secreted Zn2+ is critical for neuronal communication,
synaptic plasticity and memory formation [32]. Indeed, Zn2+ in the hippocampus is essential
for the induction of long-term potentiation (LTP), which is a form of synaptic information
storage that has become a well-known paradigm for the mechanisms underlying memory
formation.
There are two factors involved in the maintenance of Zn homeostasis, metallothioneins and Zn
transporters. Metallothioneins are ubiquitous metal-binding proteins with 68 amino acids that
bind seven metal atoms (including Zn, Cu, Cd, etc.) via 20 cysteine residues. There are three
types of metallothioneins, MT-1, MT-2 and MT-3. MT-1 and MT-2 are ubiquitously expressed
throughout the entire body, whereas MT-3 is primary localized in the central nervous system.
Zn transporters also control Zn homeostasis by facilitating Zn influx and efflux [33]. There are
two types of mammalian Zn transporters, ZnT transporters and Zrt-, Irt-like protein (ZIP)
transporters. ZnT transporters are involved with the solute carrier (SLC30) gene family and
decrease intracellular Zn via a facilitation of Zn efflux from cells. There are 14 types of ZnT
transporters in mammals, including ZnT-1 and ZnT-3, which are colocalized with chelatable
Zn in the brain. ZnT-1 is a membrane protein with six transmembrane domains and is widely
distributed in mammalian cells. ZnT-1 has a pivotal role in Zn efflux and protects against
excess Zn. ZnT-3 is localized to the membranes of presynaptic vesicles, transports Zn into
synaptic vesicles and maintains high Zn concentrations in the vesicles.
ZIP transporters are another type of Zn transporter encoded by SLC39 genes. ZIP transporters
increase cytosolic Zn by promoting transport from extracellular to intracellular compartments.
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Fourteen ZIP genes have been identified in mammals and the ZIP transporters are localized to
the cell membranes or to the membranes of the Golgi apparatus or ER. These transporters
control Zn influx into subcellular organs. The impairment of Zn transporters results in severe
diseases such as Ehlers-Danlos syndrome.
The concentration of Zn in the brain is much higher compared to Cu; therefore, Zn2+ may
influence PrPC binding to Cu [34]. Bioinformatics analysis has revealed evolutionary similari-
ties between prion genes and gene-encoding ZIP transporters [35, 36]. Among 14 transporters,
the sequential similarities exist between PrPC and ZIP5, ZIP6 and ZIP10. Taylor et al. reported
that ZIP6 and ZIP10 form heteromers similar to PrP structures and influences cell migration
[37]. PrPC colocalizes with ZIP5 and forms dimers [38]. These findings strongly suggest that
PrPC plays important roles in the neuronal regulation of Zn. Watt et al. reported that PrPC-
enhanced cellular uptake of Zn via binding with the AMPA-type glutamate receptor and that
PrPC acts as Zn sensor in the synapse [39]. Indeed, PrP facilitates Zn influx into the brain,
regulates Zn homeostasis and attenuates Zn-induced neurotoxicity.
2.3. Fe and prion protein
Fe is the most abundant metal in the brain as well as in the entire body. Fe is essential for
numerous biological functions as an enzyme cofactor for metabolic processes such as the
oxygen transport, oxidative phosphorylation and energy transfer. Fe has critical roles in spe-
cialized brain functions such as the synthesis of dopaminergic neurotransmitters and
myelination. Therefore, Fe deficiency impairs learning, especially in children or infants. The
Fe deficiency impairs working ability or learning ability also in adults. However, excess Fe can
generate reactive oxygen species (ROS) that damage DNA, proteins and lipids and can there-
fore be toxic to neurons.
Fe exists in two different forms, ferrous iron (Fe2+) and ferric iron (Fe3+). In general,
oxidized Fe3+ is insoluble and exists extracellularly, whereas reduced Fe2+ is soluble and
intracellularly located. Orally administrated Fe is primarily absorbed from the gastrointes-
tinal pathway via divalent metal transporter-1 (DMT-1) as Fe2+. Once it enters the circula-
tion, Fe2+ ions are oxidized into Fe3+ by ferroxidases such as ferritin or ceruloplasmin.
Transferrin, an iron transporter protein, binds two Fe3+ ions. Transferrin-bound iron (Fe3+)
crosses the blood brain barrier (BBB) via transferrin receptors and enters into cells. Finally,
Fe3+ is reduced into Fe2+ by ferrireductase and functions as a cofactor for neuronal
enzymes such as tyrosine hydroxylase, which is necessary for the dopamine synthesis.
Thus, Fe levels, as well as the ratio between Fe2+ and Fe3+, are strictly regulated in normal
brains.
Increasing evidence suggests that PrPC is involved in Fe homeostasis [40]. PrPC reportedly has
ferrireductase activity and modulates the cellular uptake of Fe [41]. Tripathi et al. demon-
strated that PrP induces the conversion from Fe3+ to Fe2+ and then Fe2+ is intracellularly
transported by ZIP14/DMT-1 [42]. PrP-knockout mice exhibit altered Fe metabolism [43]. PrP
is cotransported with ferritin, an iron-binding protein. Moreover, a decreased level of transfer-
rin was observed in the cerebrospinal fluid of CJD patients [44].
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2.4. Mn and prion protein
There are several studies suggesting that Mn may be a facilitator of prion diseases. Mn is an
essential trace elements and crucial for various enzymes such as hydrolase, glutamine synthe-
tase, arginase and pyruvate carboxylase [45]. However, excess Mn is neurotoxic and induces
Parkinson's disease-like syndrome.
Johnson et al. investigated the levels of trace elements in prion-infected hamster brains using
X-ray photoelectron emission microscopy with synchrotron radiation and found reduced Cu
and increased Mn in prion protein plaques [11]. Thackray et al. reported that PrPC loses its
SOD-like activity when Cu is replaced with Mn [46]. Mn enhances the survival of PrP in model
soils and increases its infectivity [47]. The risk of a prion disease in elk, termed chronic wasting
disease, was associated with an Mg deficiency and increased Mn concentrations [48]. A recent
epidemiological survey suggests a relationship between the pathogenesis of CJD and the
imbalance of Mn [49]. Moreover, the impairment of Mn transporter is reportedly involved in
the infection process [50].
3. Metal and PrPSc neurotoxicity
3.1. Metal-induced conformational changes of prion protein and its neurotoxicity
The conformational changes and neurotoxicity of PrPSc are central for the transmission and the
pathogenesis of prion disease. To investigate the neurotoxicity of PrPSc, we and other
researchers have employed synthetic fragment peptides of PrP (PrP106-126) as a model pep-
tide of PrPSc, considering the methodological difficulties of using a whole prion protein owing
to its strong infectious characteristics [51]. The structure of PrP106-126 coincides with the
proposed β-sheet structures of PrPSc [52]. PrP106-126 forms aggregates with β-sheet structures
as amyloid fibrils that share several characteristics of PrPSc, causes the apoptotic death of
cultured neurons or glial cells and possess the ability to bind to metals including Cu2+ and
Zn2+.
We synthesized three fragment peptides: PrP77-83 (WGQPHGGGWGQPHGGG), PrP106-126
(KTNMKHMAGAAAAGAVVGGLG) and PrP144-157 (DYEDRHRENMHRY). All three pep-
tides attenuated Cu2+-induced neurotoxicity [51]. Although PrP77-83 and PrP144-157 are not
neurotoxic, PrP106-126 forms β-sheet structures during the “aging” process (the incubation at
37°C for several days), as determined using the thioflavin T (ThT) fluorescence assay, far-UV
circular dichroism (CD) spectroscopy and atomic force microscopy (AFM) imaging. Moreover,
aged PrP106-126 exhibits enhanced neurotoxicity on primary cultured rat hippocampal neu-
rons. Thus, we added various trace elements or metal chelators to solutions of PrP106-126
during the aging process and evaluated its conformational changes and neurotoxicity. We
found that the coexistence of Zn2+ or Cu2+ during the aging process significantly attenuated
the neurotoxicity of PrP106-126. Moreover, the presence of Al3+, Fe2+ and Fe3+ did not result in
significant changes. We also observed the oligomerization of PrP106-126 using the fluorescent
changes of ThT, which binds with pleated β-sheet structures. The ThT fluorescence of solutions
of aged PrP106-126 increased compared to freshly dissolved PrP106-126 solutions. The ThT
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fluorescence of aged PrP106-126 with Zn2+, Fe2+, or Fe3+ was significantly decreased compared
to aged PrP106-126 alone. In particular, the addition of Cu2+ dramatically decreased ThT
fluorescence to the same level as fresh PrP106-126. Furthermore, aged PrP106-126 forms
amyloid fibrils with distinct straight and long morphology on mica plates, as observed using
AFM, although we did not observe fiber-like structures in freshly prepared PrP106-126. More-
over, aged PrP106-126 with Cu or Zn exhibited different morphological features compared to
aged PrP106-126 alone. Therefore, it is possible that Cu2+ and Zn2+ influenced the β-sheet
formation of PrP106-126 and thereafter attenuated its neurotoxicity. Our results are consistent
with other studies that demonstrate that Cu2+ inhibited the ß-sheet formation of PrP111-126 or
that Cu2+ inhibited the conformational changes of the larger fragment [53]. Thakur et al.
reported that Cu2+ did not induce the oligomerization of PrP at physiological temperature
and that Cu2+ may act as an attenuator in prion diseases [54].
3.2. Molecular mechanism of the neurotoxicity induced by PrP106-126
Understanding the pathway for PrPSc-induced neurodegeneration is of particular importance
for identifying substances that protect against prion diseases. PrP106-126 causes adverse
effects, such as the proliferation of microglia, the induction of pro-inflammatory responses,
the production of reactive oxygen species (ROS) and the activation of ER stress. Our review
focuses the disruption of Ca homeostasis, because Ca2+ ions are required for various functions
of key enzymes such as kinases, phosphatases and proteases. The disruption of neuronal Ca
homeostasis and alteration of intracellular calcium Ca2+ levels ([Ca2+]i) activated, various
apoptotic proteins such as calpain and caspase, leading to neuronal death. The disruption of
Ca homeostasis might trigger various adverse effects that are also associated with prion
diseases.
Support of this idea was first demonstrated in a study of the neurotoxicity of AβP [55–57]. In
1993, Arispe et al. demonstrated that AβP(1–40), i.e., the first 40-residues of AβP, directly
incorporates into artificial lipid bilayer membranes and forms cation-selective ion channels
[58]. The channels, termed “amyloid channels,” are giant multilevel pores and can allow a
large amount of Ca2+ to pass through them. Their activity can be blocked by Zn2+ ions. We
observed the appearance of amyloid channels on membrane patches from a neuroblastoma
cell line (GT1-7 cells). GT1-7 cells possess neuron-like characteristics, such as the expression of
neuron-specific proteins, the expression of various channels and receptors and the extension of
neuritis [59]. After the administration of AβP(1–40), the current derived from the amyloid
channels appeared. The activity of amyloid channels was inhibited by the addition of Zn2+
and recovered by the administration of o-phenanthroline (a Zn chelator). Based on these
findings, we proposed the hypothesis termed the “amyloid channel hypothesis.” This hypoth-
esis demonstrates that the direct binding of AβPs on membranes and the subsequent disrup-
tion of Ca2+ homeostasis through amyloid channels might be the primary event in AβP
neurotoxicity. AβP might have a similar mechanism of toxicity as that underlies the toxicity of
various antimicrobial or antifungal peptides that also exhibit channel-forming activity and cell
toxicity [60]. Indeed, Soscia et al. demonstrated that AβP exerts antimicrobial activity against
eight common and clinically relevant microorganisms [61]. Furthermore, the presence of pore-
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like structures of AβPs was demonstrated in the neuronal cell membrane of the brains of AD
patients and AD-model mice [62].
Increasing evidence suggests that other amyloidogenic proteins also form pores and disrupts
Ca homeostasis. Lashuel et al. used electron microscopy to show that α-synuclein, a DLB-
related protein with 141 amino acid residues, forms annular pore-like structures [63]. Lal et al.
investigated the oligomerization and conformational changes of AβP, α-synuclein, islet amy-
loid peptide (amylin) and other amyloidogenic proteins using gel electrophoresis and AFM
imaging [64]. Their results demonstrate that these amyloidogenic proteins form annular chan-
nel-like structures on bilayer membranes. Electrophysiological and morphological studies
have revealed that PrP forms amyloid channels similar to AβP. PrP106-126 reportedly forms
cation-permeable pores in artificial lipid bilayers as well as AβP [65]. Zn2+ also inhibited the
activity of PrP channels. Kourie et al. found that PrP106-126 was directly incorporated into the
lipid bilayers and formed cation-selective, Cu-sensitive ion channels and that quinacrine (a
potent therapeutic drug for prion diseases) inhibited the currents induced by PrP channels
[66]. Demuro et al. reported that AβP, human amylin, prion and polyglutamine increased the
elevation of [Ca2+]i in a conformation-dependent manner [67]. Furthermore, a recombinant PrP
protein (PrP90-231) formed channels through artificial lipid bilayers [68]. PrP has microbial
activity similar to AβP [69].
We observed temporal changes in [Ca2+]i within GT1-7 cells using a high-resolution multisite
video imaging system with fura-2 as the cytosolic free fluorescent calcium reporter probe [70].
Shortly after exposure to PrP106-126, a marked increase in [Ca2+]i occurred within many
neurons, as well as an increase in AβP. Moreover, scrambled PrP106-126 (a nontoxic and
nonamyloidogenic analogue with the random sequence of PrP106-126) did not cause such an
elevation. These findings strongly suggest that the disruption of Ca homeostasis via unregulated
amyloid channels may be the molecular basis of the neurotoxicity of prion diseases and other
conformational diseases.
3.3. Protective substances against PrP106-126-induced neurotoxicity
Substances that prevent the neurotoxicity of PrPSc are of particular interest for screening
preventive drugs for the treatment of prion diseases. Trace elements can induce conforma-
tional changes in AβP; therefore, clioquinol (5-chloro-7-iodo-8-quinolinol), a chelator of Zn
and Cu and its derivatives have been used in therapeutic trials for AD [71]. Clioquinol also
affected scrapie-induced memory impairment [72] and D-(-)-penicillamine, a Cu2+-specific
chelator, attenuated the pathogenesis of prion diseases in vivo [73]. Furthermore, small
peptides, such as that the β-sheet breaker peptide, inhibit the conformational changes of
PrP and AβP [74]. Our survey for substances that protect against PrP106-126-induced neu-
rotoxicity revealed that carnosine (β-alaninyl histidine) might be a candidate for treatment of
prion diseases. Carnosine is a water-soluble dipeptide that is contained in mammalian
muscle and brain and particularly in the olfactory bulbs [75]. Carnosine has antioxidant,
anticross-linking, antiglycosylation activities and the ability to bind to metals (Figure 2).
Carnosine inhibits the oligomerization of AβP and attenuates neurodegeneration in AD
model mice [76]. We have reported that carnosine inhibits Zn2+-induced neuronal death
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which plays a central role in the pathogenesis of vascular-type senile dementia [77]. Consid-
ering these beneficial characteristics of carnosine, carnosine may act as a neuroprotector in
the brain. Based on these findings, we published a patent for carnosine as a possible target
for drugs for vascular type senile dementia [78].
4. Hypothesis: link between trace elements in the pathogenesis of prion
diseases
4.1. PrPC as a controller of metal homeostasis at the synapse
Considering the results of our study together with those of the other studies, we propose the
following hypothetical mechanism regarding the role of PrP and the neurodegeneration pro-
cesses underlying prion diseases (Figure 3). PrPC and other various proteins including
Alzheimer's APP, receptors, such as the NMDA-type glutamate receptor or AMPA-type gluta-
mate receptor, are colocalized at the synapse. Synapses are critical nodes for the processing of
neural information and the memory formation in neural networks. Thus, disorders of the
synapses are the primary symptoms of neurodegenerative diseases. APP is localized to the
presynaptic region of synapses and AβP is secreted into synaptic clefts in the presence of
neuronal stimuli [79]. Meanwhile, PrPC is localized to the postsynaptic membrane and is
coupled to glutamate receptors [24]. Both of PrPC and APP are metal-binding proteins and
regulate metal homeostasis. The synaptic cleft is considered to be cylindrical with a radius of
120 nm and a height of 20 nm; it composes ∼1% of the extracellular volume and ∼20% of the
total brain volume [80]. Zn and Cu are released into this small compartment at the micromolar
levels. Therefore, APP and PrPC likely interact with each other in this small compartment,
which is filled with Zn and Cu.
Figure 2. Structure and roles of carnosine.
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PrPC regulates the cellular uptake of Cu, Zn and Fe as discussed previously. PrPC, an analogue
of ZIP transporters, is localized to the postsynaptic membrane, binding with the AMPA-type
glutamate receptor, which facilitates Zn influx. The ZnT-1 transporter, which enhances Zn
efflux into the extracellular compartment, is also localized to the postsynaptic membrane and
regulates the activity of the NMDA-type glutamate receptor [81, 82]. Thus, synaptic Zn levels
are likely controlled by both ZnT-1 and PrPC. In comparison, MT-3 that is secreted from
neurons or glia may regulate Zn homeostasis at synapses. Uchida et al. found that neuronal
growth inhibitory factor (GIF) that inhibits neurite extensions and prevents neuronal death
was decreased in the brains of AD patients and determined that GIF is equivalent to MT-3 [83].
Therefore, MT-3 (GIF) is implicated in AD-associated neuronal death. Considering our results
and other numerous findings, carnosine may be another regulator of metal homeostasis in the
synapse, similar to MT-3; carnosine is synthesized in glial cells (astrocytes and oligodendro-
cytes) and secreted into synaptic clefts after the glutamate response.
Figure 3. Hypothetical model of the physiological roles of normal prion protein at the synapse. Zn2+ and glutamate
accumulate in synaptic vesicles and are released into synaptic clefts during neuronal excitation. Zn2+ regulates Ca2+ influx
through glutamate receptors (NMDA-R, Ca-A/K), modulates neuronal information and is implicated in the maintenance
of synaptic plasticity and memory formation, similar to Ca2+. Zn has important roles in neural communication. Cu2+ is
also released into synaptic vesicles and regulates various receptors, similar to Zn2+. APP is present in the presynaptic
domain and PrPC is localized to the postsynaptic domain. These proteins are closely associated with the synaptic cleft and
have cytoprotective roles via the regulation of metal homeostasis and protection against free radicals. PrPC binds to the
AMPA-type glutamate receptors and regulates Zn2+ levels similar to ZIP Zn transporters. Additionally, the ZnT-1 Zn
transporter is localized to postsynaptic membranes that express NMDA-type glutamate receptors and regulates Zn
homeostasis. Moreover, PrPC has SOD activity and also regulates Cu2+ levels, which influence APP processing. APP
converts Cu2+ into Cu+ and regulates Cu at the synapse. PrPC has ferrireductase activity, which converts Fe3+ to Fe2+. APP
binds to ferroportin and thereby regulates Fe2+ efflux. MT-3 and carnosine are released from glial cells, into synaptic clefts
and are also implicated in the regulation of excess Zn. Abbreviations: ZnT-1, zinc transporter 1; AMPA-R, AMPA-type
glutamate receptor; NMDA-R, NMDA-type glutamate receptor; MT-3, metallothionein 3.
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PrPC also regulates the level of Fe and the ratio between Fe3+ and Fe2+ as a ferrireductase. APP
binds to a Fe transporter, ferroportin and regulates Fe efflux. Furthermore, PrPC regulates Cu,
which influences the expression of APP and the production of AβP. The roles of APP and PrPC in
the maintenance of metal homeostasis are essential for normal brain function; therefore, a
disruption of this homeostasis may trigger the degeneration of synapses and ultimately lead to
the pathogenesis observed in AD or prion diseases. Recent studies demonstrate that PrPC plays
critical roles in the cleavage of APP and the regulation of AβP levels [84]. PrPC reportedly
attenuates the oligomerization of AβP and the neurotoxicity [85]. Considering these results
together, PrPC is crucial for neuroprotection and the regulation of various neuronal processes
because it modulates SOD, protects cells from free radicals and controls AβP neurotoxicity.
However, under pathological conditions (Figure 4), PrPSc enters into the brain via the ingestion
of contaminated food, for example and then triggers the conformational conversion of PrPC
into PrPSc. Mn may act in these pathways. The loss of neuroprotective PrPC induces the
dyshomeostasis of trace elements and ultimately leads to apoptotic death of neurons. Excess
Zn or Cu influences APP, induces conformational changes of AβP and enhances its neurotox-
icity. Oligomerized PrPSc, as well as AβP, form pores in synaptic membrane, causing the
disruption of Ca homeostasis, ultimately leading to apoptotic neuronal death. This working
hypothesis offers insight into the mechanism of prion diseases.
Figure 4. Hypothetical model of prion disease pathogenesis. In the pathological condition, PrPSc enters the brain and
triggers the conversion of PrPC, which depletes PrPC and accumulates of PrPSc. The loss of the neuroprotective functions
of PrPC induces oxidative stress, enhance AβP neurotoxicity and ultimately lead to neuronal death. The accumulated
PrPSc forms Ca2+-permeable pores in the membrane and disrupted Ca2+ homeostasis. The imbalance of metals at the
synapse triggers conformational changes in AβP, which enhances its neurotoxicity via the formation of Ca2+-permeable
pores. Subsequent Ca2+ dyshomeostasis leads to neuronal death.
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In conclusion, our results shed light on the enigmatic roles of trace elements in the pathogen-
esis of prion diseases. However, further research is necessary particularly regarding the inhib-
itory mechanism of carnosine and the development of possible protective agents for prion
diseases.
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